and multiday chemotherapy were studied. Study designs included large trials that were randomized and double-blinded; randomized, open label; open label; crossover; and retrospective reports. Reports with small numbers of patients were included in Table 1 . Table 1 also includes the history of chemotherapy administration because it can substantially influence the results of an antiemetic trial. Populations were consistent within studies in terms of patient gender, alcohol use, or exclusion criteria such as complaints of nausea or vomiting in the immediate period before chemotherapy was administered. Table 1 lists the number of patients included in each treatment arm.
Response rates in the table reflect complete responses, that is, no emetic episodes and no use of rescue medications. If a drug was reported to be statistically better, then it is noted in the column after complete response rates.
None of the randomized, double-blinded trials found a statistical difference in efficacy rates between granisetron and ondansetron. The studies with a lessrigid design also showed equivalency between the 2 agents, with a few exceptions. Yalcin et al. 28 reported an advantage to using granisetron, 3 mg intravenously, over ondansetron, 8 mg intravenously, for moderately emetogenic chemotherapy. Study size was small at 18 or 19 patients per study arm. In a retrospective review of antiemetic therapy, Dempsey et al. 38 found that ondansetron, 8 mg intravenously, was inferior to granisetron, 10 mcg/kg per dose. The study arms differed in that the ondansetron group was exposed to radiation more often, and corticosteroid use was less frequent in the ondansetron arm. Equivalent efficacy was also mostly reported in the setting of bone marrow transplants. The trial by Spitzer et al. 16 showed a numerical superiority of granisetron over ondansetron, but the study arms were too small for statistical analysis. Lacerda et al. 20 observed that ondansetron, 24 mg/d, was superior to granisetron, but that 16 mg/d of ondansetron was equivalent. Only 16 and 24 patients were included in the study arms for ondansetron, 16 mg and 24 mg, respectively.
For delayed emesis, efficacy was also similar among the first-generation 5-HT3 antagonists. A single dose of granisetron was reported by Stewart et al. 11 to be less effective against delayed nausea than a multi-day regimen of ondansetron. An argument can be made that these were not equivalent doses. The period greater than 24 hours almost always showed less efficacy than the acute period.
In a meta-analysis of 14 studies and 6467 patients comparing ondansetron with granisetron in the prophylaxis of acute or delayed nausea and vomiting in the setting of highly emetogenic or moderately emetogenic chemotherapy, del Giglio et al. 48 showed an apparent equivalency between the 2 agents. Likewise, no significant differences in adverse effects occurred, except that patients receiving 32 mg of ondansetron intravenously experienced blurred vision and dizziness more often. 8 The more common side effects were headache, constipation, and diarrhea.
Dolasetron and ondansetron were compared in a trial for moderately emetogenic agents by Fauser et al. 40 Dolasetron, 200 mg orally, was equivalent to multiple doses of ondansetron, 8 mg. Audhuy et al. 42 published a report showing intravenous granisetron and intravenous dolasetron to be equivalent in managing acute nausea and vomiting after treatment with highly emetogenic agents.
Palonosetron is a second-generation 5-HT3 antagonist. Three randomized, placebo-controlled, noninferiority trials compared this newer agent with first-generation 5-HT3 antagonists. Gralla et al. 45 compared 2 dose levels of palonosetron with a single dose of ondansetron, 32 mg intravenously, in the management of nausea and vomiting after treatment with moderately emetogenic chemotherapy in chemotherapy-naive and -non-naive patients not treated with steroids. Palonosetron, 0.25 mg intravenously, was statistically better than ondansetron in both complete control of acute nausea and vomiting and delaying nausea and vomiting.
Palonosetron, 0.75 mg, was found to have no statistical difference from ondansetron. Aapro et al. 46 studied palonosetron, 0.25 mg intravenously and 0.75 mg intravenously, against ondansetron, 32 mg intravenously, in both chemotherapy-naive and -non-naive patients with and without steroids undergoing highly emetogenic regimens. The 2 drugs showed no statistical difference either during the acute or the delayed phases.
Eisenberg et al. 47 compared dolasetron, 100 mg intravenously, with palonosetron, 0.25 mg intravenously and 0.75 mg intravenously, after moderately emetogenic chemotherapy in chemotherapy-naive and -non-naive patients. A small percentage of patients 49 reported on the safety of 3-day therapy with palonosetron in normal subjects. Brames et al. 50 used dexamethasone daily and palonosetron on days 1, 3, and 5 of fractionated cisplatin therapy (bleomycin and etoposide or etoposide alone) for testicular cancer and found the therapy to be at least as effective and safe as historical controls involving ondansetron. Palonosetron is at least as effective as first-generation 5-HT3 antagonists against acute nausea and vomiting. The primary goal of the above trials was to prove noninferiority of palonosetron to the first-generation 5-HT3 antagonists, and that goal was achieved. No trials have been designed to prove the superiority of palonosetron over other agents in its class. The comparative efficacy of palonosetron against delayed nausea and vomiting cannot be fully determined until trials have been conducted with other agents dosed appropriately to provide a pharmacologic effect throughout the study period, including the acute and delayed phases.
Steroids and aprepitant have emerged as the favored agents to prevent nausea and vomiting in the delayed phase after highly emetogenic chemotherapy. The current recommended antiemetic treatment strategies for moderately and highly emetogenic chemotherapy use combinations of 5-HT3 antagonists, steroids, and aprepitant.
1,2 As the 2006 ASCO guidelines 2 point out, "The superiority question has now evolved to whether or not palonosetron is better than other 5-HT3 antagonists when they are combined with both dexamethasone and aprepitant."
At equivalent doses, the 5-HT3 antagonists may be judged as similar in efficacy and safety, and other factors, such as cost or convenience, can be considered in choosing between them. These agents have pharmacologic differences in terms of absorption, half-life, receptor-binding affinity, selectivity of binding sites, and metabolism (Table 2) . Bioavailability for the firstgeneration 5-HT3 antagonists allows for oral administration. Palonosetron is unlikely to be available orally because of extensive first-pass effect. As the results of the clinical trials indicate, oral administration of the other agents has similar efficacy.
Despite the shorter half-life seen with ondansetron, all of the first-generation 5-HT3 antagonists seem to able to be administered daily with similar efficacy, suggesting a dissociation of duration of action from half-life. Ondansetron has displayed activity at various receptors other than 5-HT3 receptors. These include 5-HT1A, 5-HT1B, ␣1-adrenergic, and µ-opioid receptors. Palonosetron also binds to 5-HT␣1A, 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, muscarinic M 2, and -and ␦-opiod receptors. Obvious differences in the incidence of adverse effect related to these additional binding sites have not been reported consistently in the clinical trials.
The primary metabolic pathway for ondansetron is hydroxylation on the indole ring followed by glucuronide or sulfate conjugation, with some nonconjugated active metabolites. Granisetron metabolism involves N-demethylation and aromatic ring oxidation followed by conjugation. Some metabolites may also have 5-HT3 receptor antagonist activity.
Dolasetron is reduced to hydrodolasetron by a ubiquitous enzyme, carbonyl reductase. CYP2D6 is primarily responsible for the subsequent hydroxylation of hydrodolasetron and both CPT3A and flavin monooxygenase are responsible for N-oxidation of hydrodolasetron. Palonosetron is metabolized to N-oxide-palonosetron and 6-S-hydroxy-palonosetron. Metabolites have very weak antagonist activity. CYP2D6 and, to a lesser extent, CYP3A and CYP1A2 are involved in metabolizing palonosetron. Kinetic parameters of palonosetron are not significantly different between poor and extensive metabolizers of 40 Original Article CYP2D6 substrates. The enzymes involved in metabolizing the 5-HT3 antagonists are listed in Table 2 . Metabolism does not appear to have a major influence on the results seen in clinical trials.
Ultrarapid metabolizers have been reported in association with CYP2D6. Kaiser et al. 51 reported on CYP2D6 genotypes influencing emetic control after ondansetron use, showing that patients experiencing failed treatment with 5-HT3 antagonists may benefit from treatment with an agent not metabolized by CYP2D6. The incidence of ultra metabolizers is variable across different populations: Saudis 21%, Ethiopians 18%, Sephardic Jews 13%, Italians 8%, and Caucasians 1% to 8%. 51 de Wit et al. 39 rescued patients experiencing ondansetron failures who were undergoing highly emetogenic chemotherapy. In a randomized, double-blind study, either granisetron, 3 mg intravenously with dexamethasone, or ondansetron, 8 mg intravenously with dexamethasone, was given on the second cycle. Compared with only 5% of the ondansetron group, 47% of the granisetron group experienced complete protection. de Wit et al. 39 concluded that the presence of no cross-tolerance among 5-HT3 antagonists and the changing of medications within the class have significant potential to provide antiemetic efficacy. Whether differences in enzyme metabolism can fully explain a lack of cross tolerance is unknown.
Summary
Clinical trials support a policy of considering the 5-HT3 antagonists therapeutically similar in efficacy and safety. The minor differences in half-life, receptor binding, and metabolism may influence adaptations to a treatment plan but do not play a major role in the initial selection of a 5-HT3 antagonist.
